Cyprumed Partners with MSD on Oral Peptide Therapeutics

Cyprumed GmbH, based in Innsbruck, Austria, has entered into a license and option agreement with MSD to develop oral peptide therapeutics. MSD, known for peptide therapeutics, will utilize Cyprumed's delivery technology to advance oral formulations. This agreement allows MSD non-exclusive global rights to Cyprumed's delivery platform for unspecified targets. Additionally, MSD holds an option for exclusive licensing for specific targets.

Under the terms, Cyprumed could earn up to $493 million through upfront payments, regulatory milestones, and net sales. Moreover, Cyprumed might receive further payments if MSD takes up the Exclusive License Option. MSD will handle research, development, and commercialization of products using Cyprumed technology.

Florian Föger, CEO of Cyprumed, highlighted the importance of this collaboration, emphasizing the scalability of their drug delivery technology. Allen C. Templeton of MSD expressed eagerness in working with Cyprumed to further develop macrocyclic peptides.